ABT
Abbott Laboratories
Price Chart
Latest Quote
$109.41
Current Price| Previous Close | $109.30 |
| Open | $109.23 |
| Day High | $111.00 |
| Day Low | $108.87 |
| Volume | 11,429,020 |
Stock Information
| Quarterly Dividend / Yield | $2.52 / 2.31% |
| Shares Outstanding | 1.74B |
| Total Debt | $12.97B |
| Cash Equivalents | $7.73B |
| Revenue | $44.33B |
| Net Income | $6.52B |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $190.42B |
| P/E Ratio | 29.41 |
| EPS (TTM) | $3.72 |
| Exchange | NYQ |
📊 Custom Metrics & Score
Score: 8/42| Debt to Equity | 0.32 |
| Current Ratio | 1.67 |
| Quick Ratio | 1.23 |
| Avg Revenue Growth | -0.65% |
| Avg FCF Growth | -6.64% |
| FCF Yield | 3.34% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $109.41 | 11,437,885 |
| 2026-01-30 | $109.30 | 17,529,400 |
| 2026-01-29 | $106.09 | 15,687,900 |
| 2026-01-28 | $106.05 | 15,120,500 |
| 2026-01-27 | $108.27 | 16,594,500 |
| 2026-01-26 | $108.77 | 19,094,200 |
| 2026-01-23 | $107.42 | 21,813,100 |
| 2026-01-22 | $108.61 | 37,099,400 |
| 2026-01-21 | $120.73 | 12,557,300 |
| 2026-01-20 | $121.14 | 12,634,000 |
| 2026-01-16 | $121.76 | 10,418,200 |
| 2026-01-15 | $123.53 | 7,079,500 |
| 2026-01-14 | $124.37 | 7,187,800 |
| 2026-01-13 | $123.67 | 5,169,800 |
| 2026-01-12 | $124.01 | 5,524,300 |
| 2026-01-09 | $125.29 | 4,317,600 |
| 2026-01-08 | $125.54 | 4,344,600 |
| 2026-01-07 | $126.40 | 6,632,300 |
| 2026-01-06 | $127.14 | 8,327,500 |
| 2026-01-05 | $125.81 | 6,548,500 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
📰 Latest News
Abbott’s Exact Sciences Deal Recasts Diagnostics While Nutrition Faces Reset
Simply Wall St. • 2026-02-02T20:12:46Z
The Best Dividend King to Buy With $150
Motley Fool • 2026-02-02T17:05:00Z
NVST or ABT: Which Is the Better Value Stock Right Now?
Zacks • 2026-02-02T16:40:02Z
4 Medical Product Stocks to Watch From a Challenging Industry
Zacks • 2026-02-02T14:08:00Z
Freedom Capital Upgrades Abbott Laboratories (ABT) to Buy
Insider Monkey • 2026-02-01T07:38:48Z
Abbott Laboratories Resets Portfolio With Exact Sciences Cancer Diagnostics Deal
Simply Wall St. • 2026-01-31T17:10:33Z
Decent Organic Sales Growth Expected for Abbott Laboratories (ABT) in 2026
Insider Monkey • 2026-01-30T19:31:34Z
Senseonics wins CE mark for one-year CGM
MedTech Dive • 2026-01-30T10:00:00Z
Applied Materials leads Zacks' latest Analyst Blog, with strong semiconductor momentum offset by rising trade and cost pressures.
Zacks • 2026-01-30T09:29:00Z
Top Analyst Reports for Applied Materials, Linde & Abbott
Zacks • 2026-01-29T22:19:00Z
Income Statement (Annual)
Revenue
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | - | $17,366,000,000 | $16,698,000,000 | $17,888,000,000 |
| Cost Of Revenue | - | $18,706,000,000 | $17,975,000,000 | $19,142,000,000 |
| Total Revenue | - | $41,950,000,000 | $40,109,000,000 | $43,653,000,000 |
| Operating Revenue | - | $41,950,000,000 | $40,109,000,000 | $43,653,000,000 |
Expenses
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Interest Expense | - | $559,000,000 | $637,000,000 | $558,000,000 |
| Total Expenses | - | $35,125,000,000 | $33,631,000,000 | $35,291,000,000 |
| Other Income Expense | - | $403,000,000 | $438,000,000 | $319,000,000 |
| Other Non Operating Income Expenses | - | $376,000,000 | $479,000,000 | $321,000,000 |
| Net Non Operating Interest Income Expense | - | $-215,000,000 | $-252,000,000 | $-375,000,000 |
| Interest Expense Non Operating | - | $559,000,000 | $637,000,000 | $558,000,000 |
| Operating Expense | - | $16,419,000,000 | $15,656,000,000 | $16,149,000,000 |
Income & Earnings
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | - | $13,402,000,000 | $5,723,000,000 | $6,933,000,000 |
| Net Interest Income | - | $-215,000,000 | $-252,000,000 | $-375,000,000 |
| Interest Income | - | $344,000,000 | $385,000,000 | $183,000,000 |
| Normalized Income | - | $13,380,670,000 | $5,758,219,000 | $6,934,669,396 |
| Net Income From Continuing And Discontinued Operation | - | $13,402,000,000 | $5,723,000,000 | $6,933,000,000 |
| Total Operating Income As Reported | - | $6,825,000,000 | $6,478,000,000 | $8,362,000,000 |
| Net Income Common Stockholders | - | $13,402,000,000 | $5,723,000,000 | $6,933,000,000 |
| Net Income | - | $13,402,000,000 | $5,723,000,000 | $6,933,000,000 |
| Net Income Including Noncontrolling Interests | - | $13,402,000,000 | $5,723,000,000 | $6,933,000,000 |
| Net Income Continuous Operations | - | $13,402,000,000 | $5,723,000,000 | $6,933,000,000 |
| Pretax Income | - | $7,013,000,000 | $6,664,000,000 | $8,306,000,000 |
| Interest Income Non Operating | - | $344,000,000 | $385,000,000 | $183,000,000 |
| Operating Income | - | $6,825,000,000 | $6,478,000,000 | $8,362,000,000 |
| Depreciation Amortization Depletion Income Statement | - | $1,878,000,000 | $1,966,000,000 | $2,013,000,000 |
| Depreciation And Amortization In Income Statement | - | $1,878,000,000 | $1,966,000,000 | $2,013,000,000 |
| Amortization Of Intangibles Income Statement | - | $1,878,000,000 | $1,966,000,000 | $2,013,000,000 |
| Gross Profit | - | $23,244,000,000 | $22,134,000,000 | $24,511,000,000 |
| Net Income Discontinuous Operations | - | - | - | $0 |
| Special Income Charges | - | - | - | - |
Per Share Metrics
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Diluted EPS | $3.72 | $7.64 | $3.26 | $3.91 |
| Basic EPS | $3.75 | $7.74 | $3.30 | $3.99 |
Other
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Diluted Average Shares | $1,749,000,000 | $1,748,000,000 | $1,749,000,000 | $1,764,000,000 |
| Basic Average Shares | $1,738,871,947 | $1,731,697,991 | $1,734,076,358 | $1,737,795,021 |
| Tax Effect Of Unusual Items | - | $5,670,000 | $-5,781,000 | $-330,604 |
| Tax Rate For Calcs | - | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | - | $10,763,000,000 | $10,585,000,000 | $12,133,000,000 |
| Total Unusual Items | - | $27,000,000 | $-41,000,000 | $-2,000,000 |
| Total Unusual Items Excluding Goodwill | - | $27,000,000 | $-41,000,000 | $-2,000,000 |
| Reconciled Depreciation | - | $3,218,000,000 | $3,243,000,000 | $3,267,000,000 |
| EBITDA (Bullshit earnings) | - | $10,790,000,000 | $10,544,000,000 | $12,131,000,000 |
| EBIT | - | $7,572,000,000 | $7,301,000,000 | $8,864,000,000 |
| Diluted NI Availto Com Stockholders | - | $13,402,000,000 | $5,723,000,000 | $6,933,000,000 |
| Tax Provision | - | $-6,389,000,000 | $941,000,000 | $1,373,000,000 |
| Gain On Sale Of Security | - | $27,000,000 | $-41,000,000 | $-2,000,000 |
| Amortization | - | $1,878,000,000 | $1,966,000,000 | $2,013,000,000 |
| Research And Development | - | $2,844,000,000 | $2,741,000,000 | $2,888,000,000 |
| Selling General And Administration | - | $11,697,000,000 | $10,949,000,000 | $11,248,000,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $17,909,000,000 | $6,109,000,000 | $3,433,000,000 | $-168,000,000 |
| Total Assets | $81,414,000,000 | $73,214,000,000 | $74,438,000,000 | $75,196,000,000 |
| Total Non Current Assets | $57,758,000,000 | $50,544,000,000 | $49,214,000,000 | $50,957,000,000 |
| Other Non Current Assets | $16,459,000,000 | $7,097,000,000 | $6,033,000,000 | $5,212,000,000 |
| Investmentin Financial Assets | $553,000,000 | $555,000,000 | $558,000,000 | - |
| Goodwill And Other Intangible Assets | $29,755,000,000 | $32,494,000,000 | $33,253,000,000 | $35,970,000,000 |
| Other Intangible Assets | $6,647,000,000 | $8,815,000,000 | $10,454,000,000 | $12,739,000,000 |
| Current Assets | $23,656,000,000 | $22,670,000,000 | $25,224,000,000 | $24,239,000,000 |
| Inventory | $6,194,000,000 | $6,570,000,000 | $6,173,000,000 | $5,157,000,000 |
| Receivables | $9,495,000,000 | $8,821,000,000 | $8,881,000,000 | $8,833,000,000 |
| Other Receivables | $2,570,000,000 | $2,256,000,000 | $2,663,000,000 | $2,346,000,000 |
| Accounts Receivable | $6,925,000,000 | $6,565,000,000 | $6,218,000,000 | $6,487,000,000 |
| Allowance For Doubtful Accounts Receivable | $-439,000,000 | $-444,000,000 | $-500,000,000 | $-519,000,000 |
| Gross Accounts Receivable | $7,364,000,000 | $7,009,000,000 | $6,718,000,000 | $7,006,000,000 |
| Cash Cash Equivalents And Short Term Investments | $7,967,000,000 | $7,279,000,000 | $10,170,000,000 | $10,249,000,000 |
| Cash And Cash Equivalents | $7,616,000,000 | $6,896,000,000 | $9,882,000,000 | $9,799,000,000 |
| Non Current Deferred Assets | - | - | $6,033,000,000 | $5,212,000,000 |
| Non Current Deferred Taxes Assets | - | - | $6,033,000,000 | $5,212,000,000 |
| Prepaid Assets | - | - | - | $2,346,000,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Debt | $6,509,000,000 | $7,783,000,000 | $6,891,000,000 | $8,251,000,000 |
| Total Debt | $15,021,000,000 | $15,628,000,000 | $17,716,000,000 | $19,006,000,000 |
| Long Term Debt And Capital Lease Obligation | $13,521,000,000 | $14,548,000,000 | $15,465,000,000 | $18,252,000,000 |
| Long Term Debt | $12,625,000,000 | $13,599,000,000 | $14,522,000,000 | $17,296,000,000 |
| Current Debt And Capital Lease Obligation | $1,500,000,000 | $1,080,000,000 | $2,251,000,000 | $754,000,000 |
| Current Debt | $1,500,000,000 | $1,080,000,000 | $2,251,000,000 | $754,000,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $33,513,000,000 | $34,387,000,000 | $37,533,000,000 | $39,172,000,000 |
| Total Non Current Liabilities Net Minority Interest | $19,356,000,000 | $20,546,000,000 | $22,044,000,000 | $26,067,000,000 |
| Other Non Current Liabilities | $2,373,000,000 | $2,386,000,000 | $3,804,000,000 | $3,685,000,000 |
| Tradeand Other Payables Non Current | $1,070,000,000 | $1,080,000,000 | - | - |
| Non Current Deferred Liabilities | $512,000,000 | $568,000,000 | $991,000,000 | $1,392,000,000 |
| Non Current Deferred Taxes Liabilities | $512,000,000 | $568,000,000 | $991,000,000 | $1,392,000,000 |
| Current Liabilities | $14,157,000,000 | $13,841,000,000 | $15,489,000,000 | $13,105,000,000 |
| Payables And Accrued Expenses | $12,657,000,000 | $12,761,000,000 | $13,238,000,000 | $12,351,000,000 |
| Payables | $6,434,000,000 | $6,392,000,000 | $6,475,000,000 | $5,909,000,000 |
| Other Payable | $621,000,000 | $650,000,000 | $638,000,000 | $364,000,000 |
| Dividends Payable | $1,024,000,000 | $955,000,000 | $887,000,000 | $831,000,000 |
| Total Tax Payable | $594,000,000 | $492,000,000 | $343,000,000 | $306,000,000 |
| Income Tax Payable | $594,000,000 | $492,000,000 | $343,000,000 | $306,000,000 |
| Accounts Payable | $4,195,000,000 | $4,295,000,000 | $4,607,000,000 | $4,408,000,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $47,664,000,000 | $38,603,000,000 | $36,686,000,000 | $35,802,000,000 |
| Total Equity Gross Minority Interest | $47,901,000,000 | $38,827,000,000 | $36,905,000,000 | $36,024,000,000 |
| Stockholders Equity | $47,664,000,000 | $38,603,000,000 | $36,686,000,000 | $35,802,000,000 |
| Gains Losses Not Affecting Retained Earnings | $-7,906,000,000 | $-7,839,000,000 | $-8,051,000,000 | $-8,374,000,000 |
| Other Equity Adjustments | $-7,906,000,000 | $-7,839,000,000 | $-8,051,000,000 | $-8,374,000,000 |
| Retained Earnings | $47,261,000,000 | $37,554,000,000 | $35,257,000,000 | $31,528,000,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Treasury Shares Number | $259,774,639 | $253,807,494 | $248,724,257 | $221,191,228 |
| Ordinary Shares Number | $1,731,697,991 | $1,734,076,358 | $1,737,795,021 | $1,764,082,193 |
| Share Issued | $1,991,472,630 | $1,987,883,852 | $1,986,519,278 | $1,985,273,421 |
| Tangible Book Value | $17,909,000,000 | $6,109,000,000 | $3,433,000,000 | $-168,000,000 |
| Invested Capital | $61,789,000,000 | $53,282,000,000 | $53,459,000,000 | $53,852,000,000 |
| Working Capital | $9,499,000,000 | $8,829,000,000 | $9,735,000,000 | $11,134,000,000 |
| Capital Lease Obligations | $896,000,000 | $949,000,000 | $943,000,000 | $956,000,000 |
| Total Capitalization | $60,289,000,000 | $52,202,000,000 | $51,208,000,000 | $53,098,000,000 |
| Minority Interest | $237,000,000 | $224,000,000 | $219,000,000 | $222,000,000 |
| Treasury Stock | $16,844,000,000 | $15,981,000,000 | $15,229,000,000 | $11,822,000,000 |
| Capital Stock | $25,153,000,000 | $24,869,000,000 | $24,709,000,000 | $24,470,000,000 |
| Common Stock | $25,153,000,000 | $24,869,000,000 | $24,709,000,000 | $24,470,000,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Employee Benefits | $1,880,000,000 | $1,964,000,000 | $1,784,000,000 | $2,738,000,000 |
| Non Current Pension And Other Postretirement Benefit Plans | $1,880,000,000 | $1,964,000,000 | $1,784,000,000 | $2,738,000,000 |
| Long Term Capital Lease Obligation | $896,000,000 | $949,000,000 | $943,000,000 | $956,000,000 |
| Current Accrued Expenses | $6,223,000,000 | $6,369,000,000 | $6,763,000,000 | $6,442,000,000 |
| Investments And Advances | $886,000,000 | $799,000,000 | $766,000,000 | $816,000,000 |
| Other Investments | $333,000,000 | $244,000,000 | $208,000,000 | - |
| Available For Sale Securities | $553,000,000 | $555,000,000 | $558,000,000 | - |
| Goodwill | $23,108,000,000 | $23,679,000,000 | $22,799,000,000 | $23,231,000,000 |
| Net PPE | $10,658,000,000 | $10,154,000,000 | $9,162,000,000 | $8,959,000,000 |
| Accumulated Depreciation | $-12,082,000,000 | $-11,779,000,000 | $-11,050,000,000 | $-10,405,000,000 |
| Gross PPE | $22,740,000,000 | $21,933,000,000 | $20,212,000,000 | $19,364,000,000 |
| Construction In Progress | $2,488,000,000 | $2,064,000,000 | $1,484,000,000 | $1,304,000,000 |
| Other Properties | $15,517,000,000 | $15,179,000,000 | $14,164,000,000 | $13,528,000,000 |
| Buildings And Improvements | $4,207,000,000 | $4,161,000,000 | $4,053,000,000 | $4,007,000,000 |
| Land And Improvements | $528,000,000 | $529,000,000 | $511,000,000 | $525,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $3,700,000,000 | $3,946,000,000 | $3,805,000,000 | $3,081,000,000 |
| Work In Process | $840,000,000 | $807,000,000 | $680,000,000 | $694,000,000 |
| Raw Materials | $1,654,000,000 | $1,817,000,000 | $1,688,000,000 | $1,382,000,000 |
| Other Short Term Investments | $351,000,000 | $383,000,000 | $288,000,000 | $450,000,000 |
| Machinery Furniture Equipment | - | - | - | $13,528,000,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $6,351,000,000 | $5,059,000,000 | $7,804,000,000 | $8,648,000,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $8,558,000,000 | $7,261,000,000 | $9,581,000,000 | $10,533,000,000 |
| Cash Flow From Continuing Operating Activities | $8,558,000,000 | $7,261,000,000 | $9,581,000,000 | $10,533,000,000 |
| Operating Gains Losses | $482,000,000 | $126,000,000 | $215,000,000 | $55,000,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-2,207,000,000 | $-2,202,000,000 | $-1,777,000,000 | $-1,885,000,000 |
| Investing Cash Flow | $-2,338,000,000 | $-3,133,000,000 | $-1,740,000,000 | $-2,008,000,000 |
| Cash Flow From Continuing Investing Activities | $-2,338,000,000 | $-3,133,000,000 | $-1,740,000,000 | $-2,008,000,000 |
| Net Other Investing Changes | $9,000,000 | $22,000,000 | $22,000,000 | $26,000,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $-1,295,000,000 | $-1,227,000,000 | $-3,795,000,000 | $-2,299,000,000 |
| Financing Cash Flow | $-5,404,000,000 | $-7,091,000,000 | $-7,636,000,000 | $-5,494,000,000 |
| Cash Flow From Continuing Financing Activities | $-5,404,000,000 | $-7,091,000,000 | $-7,636,000,000 | $-5,494,000,000 |
| Cash Dividends Paid | $-3,836,000,000 | $-3,556,000,000 | $-3,309,000,000 | $-3,202,000,000 |
| Common Stock Dividend Paid | $-3,836,000,000 | $-3,556,000,000 | $-3,309,000,000 | $-3,202,000,000 |
| Net Common Stock Issuance | $-1,295,000,000 | $-1,227,000,000 | $-3,795,000,000 | $-2,299,000,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-660,000,000 | $-2,498,000,000 | $-753,000,000 | $-48,000,000 |
| Issuance Of Debt | $223,000,000 | $2,000,000 | $7,000,000 | $4,000,000 |
| Interest Paid Supplemental Data | $604,000,000 | $662,000,000 | $563,000,000 | $544,000,000 |
| Income Tax Paid Supplemental Data | $1,723,000,000 | $1,475,000,000 | $1,864,000,000 | $1,941,000,000 |
| End Cash Position | $7,616,000,000 | $6,896,000,000 | $9,882,000,000 | $9,799,000,000 |
| Beginning Cash Position | $6,896,000,000 | $9,882,000,000 | $9,799,000,000 | $6,838,000,000 |
| Effect Of Exchange Rate Changes | $-96,000,000 | $-23,000,000 | $-122,000,000 | $-70,000,000 |
| Changes In Cash | $816,000,000 | $-2,963,000,000 | $205,000,000 | $3,031,000,000 |
| Proceeds From Stock Option Exercised | $264,000,000 | $167,000,000 | $167,000,000 | $255,000,000 |
| Common Stock Payments | $-1,295,000,000 | $-1,227,000,000 | $-3,795,000,000 | $-2,299,000,000 |
| Net Issuance Payments Of Debt | $-537,000,000 | $-2,475,000,000 | $-699,000,000 | $-248,000,000 |
| Net Short Term Debt Issuance | $-100,000,000 | $21,000,000 | $47,000,000 | $-204,000,000 |
| Net Long Term Debt Issuance | $-437,000,000 | $-2,496,000,000 | $-746,000,000 | $-44,000,000 |
| Long Term Debt Payments | $-660,000,000 | $-2,498,000,000 | $-753,000,000 | $-48,000,000 |
| Long Term Debt Issuance | $223,000,000 | $2,000,000 | $7,000,000 | $4,000,000 |
| Net Investment Purchase And Sale | $-141,000,000 | $-116,000,000 | $-33,000,000 | $-96,000,000 |
| Sale Of Investment | $28,000,000 | $43,000,000 | $152,000,000 | $77,000,000 |
| Purchase Of Investment | $-169,000,000 | $-159,000,000 | $-185,000,000 | $-173,000,000 |
| Net Business Purchase And Sale | $1,000,000 | $-837,000,000 | $48,000,000 | $-53,000,000 |
| Sale Of Business | $1,000,000 | $40,000,000 | $48,000,000 | $134,000,000 |
| Purchase Of Business | $0 | $-877,000,000 | $0 | $-187,000,000 |
| Net PPE Purchase And Sale | $-2,207,000,000 | $-2,202,000,000 | $-1,777,000,000 | $-1,885,000,000 |
| Purchase Of PPE | $-2,207,000,000 | $-2,202,000,000 | $-1,777,000,000 | $-1,885,000,000 |
| Change In Working Capital | $-9,217,000,000 | $-2,475,000,000 | $-1,519,000,000 | $-771,000,000 |
| Change In Payables And Accrued Expense | $-7,672,000,000 | $-1,345,000,000 | $37,000,000 | $1,288,000,000 |
| Change In Payable | $-7,672,000,000 | $-1,345,000,000 | $37,000,000 | $1,288,000,000 |
| Change In Account Payable | $356,000,000 | $-760,000,000 | $420,000,000 | $1,288,000,000 |
| Change In Tax Payable | $-8,028,000,000 | $-585,000,000 | $-383,000,000 | $-908,000,000 |
| Change In Income Tax Payable | $-8,028,000,000 | $-585,000,000 | $-383,000,000 | $-908,000,000 |
| Change In Prepaid Assets | $-796,000,000 | $-542,000,000 | $-75,000,000 | $-312,000,000 |
| Change In Inventory | $-58,000,000 | $-232,000,000 | $-1,413,000,000 | $-456,000,000 |
| Change In Receivables | $-691,000,000 | $-356,000,000 | $-68,000,000 | $-383,000,000 |
| Changes In Account Receivables | $-691,000,000 | $-356,000,000 | $-68,000,000 | $-383,000,000 |
| Stock Based Compensation | $673,000,000 | $644,000,000 | $685,000,000 | $640,000,000 |
| Depreciation Amortization Depletion | $3,218,000,000 | $3,243,000,000 | $3,267,000,000 | $3,538,000,000 |
| Depreciation And Amortization | $3,218,000,000 | $3,243,000,000 | $3,267,000,000 | $3,538,000,000 |
| Amortization Cash Flow | $1,878,000,000 | $1,966,000,000 | $2,013,000,000 | $2,047,000,000 |
| Amortization Of Intangibles | $1,878,000,000 | $1,966,000,000 | $2,013,000,000 | $2,047,000,000 |
| Depreciation | $1,340,000,000 | $1,277,000,000 | $1,254,000,000 | $1,491,000,000 |
| Gain Loss On Investment Securities | $482,000,000 | $126,000,000 | $215,000,000 | $55,000,000 |
| Net Income From Continuing Operations | $13,402,000,000 | $5,723,000,000 | $6,933,000,000 | $7,071,000,000 |
| Change In Other Working Capital | - | $-585,000,000 | $-383,000,000 | $-908,000,000 |